Genmab A/S (NASDAQ:GMAB) Issues Earnings Results, Beats Expectations By $0.12 EPS

Posted by Brenda Bartman on Aug 6th, 2026

Genmab A/S (NASDAQ:GMAB – Get Free Report) announced its quarterly earnings results on Thursday. The company reported $0.49 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.37 by $0.12, FiscalAI reports. The firm had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.11 billion. Genmab A/S had a return on equity of 15.34% and a net margin of 21.05%.

Here are the key takeaways from Genmab A/S’s conference call:

Genmab raised its 2026 guidance, now expecting revenue of DKK 4.3–4.5 billion and operating profit of DKK 1.1–1.4 billion. Revenue growth at the midpoint is projected at 19%, while operating expenses rise only 2%, highlighting expected operating leverage.
First-half proprietary-product sales increased 37% to DKK 396 million, led by EPKINLY sales growth of 48% to DKK 312 million. Management cited accelerating U.S. community adoption, broader site activation, and strong uptake of the second-line follicular lymphoma regimen.
Genmab reported statistically significant, clinically meaningful progression-free-survival results from the phase III EPCORE DLBCL-2 study and received European approval for EPKINLY plus lenalidomide and rituximab in second-line follicular lymphoma.
Petosemtamab is being expanded into two global phase III colorectal cancer trials—frontline and second-line—in combination with chemotherapy. Management also expects frontline head-and-neck data in the fourth quarter and is positioning the asset as a potential multi-indication growth driver.
Several major catalysts are expected in the coming quarters, including Rina-S phase II and III ovarian-cancer data and frontline EPKINLY data in the fourth quarter, while petosemtamab’s second- or third-line head-and-neck readout is now expected in the first quarter of 2027. Overall-survival data for the EPKINLY DLBCL study remain immature, and outcomes for these late-stage programs are still subject to clinical and regulatory uncertainty.

Genmab A/S Stock Performance

NASDAQ GMAB traded up $0.57 during trading hours on Thursday, reaching $29.83. The company’s stock had a trading volume of 5,232,595 shares, compared to its average volume of 1,988,784. The company has a current ratio of 2.18, a quick ratio of 2.17 and a debt-to-equity ratio of 0.87. The business has a 50-day simple moving average of $27.22 and a 200 day simple moving average of $27.99. Genmab A/S has a 52 week low of $21.00 and a 52 week high of $35.43. The stock has a market cap of $18.60 billion, a PE ratio of 22.60, a PEG ratio of 1.84 and a beta of 0.83.

Analyst Upgrades and Downgrades

A number of brokerages have commented on GMAB. Truist Financial initiated coverage on shares of Genmab A/S in a report on Wednesday, May 27th. They issued a “buy” rating and a $40.00 price objective on the stock. The Goldman Sachs Group upgraded Genmab A/S from a “neutral” rating to a “buy” rating in a research note on Wednesday, April 22nd. HC Wainwright increased their price objective on shares of Genmab A/S from $38.00 to $40.00 and gave the company a “buy” rating in a research note on Thursday, July 2nd. New Street Research set a $43.00 target price on shares of Genmab A/S in a research note on Wednesday, July 22nd. Finally, Weiss Ratings upgraded Genmab A/S from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Tuesday, July 28th. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $39.28.

View Our Latest Report on Genmab A/S

Institutional Trading of Genmab A/S

Large investors have recently added to or reduced their stakes in the business. Kestra Advisory Services LLC bought a new stake in shares of Genmab A/S during the 4th quarter worth about $96,000. CANADA LIFE ASSURANCE Co boosted its position in shares of Genmab A/S by 43.4% in the fourth quarter. CANADA LIFE ASSURANCE Co now owns 4,522 shares of the company’s stock worth $139,000 after buying an additional 1,369 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new stake in Genmab A/S during the 4th quarter worth about $188,000. Rossby Financial LCC acquired a new stake in shares of Genmab A/S during the 4th quarter valued at $102,000. Finally, Bellevue Group AG bought a new position in Genmab A/S during the third quarter valued at approximately $92,000. 7.07% of the stock is currently owned by institutional investors and hedge funds.

Genmab A/S Company Profile

(Get Free Report)

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.